Illumina
Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
CEO photo:
Website: www.illumina.com
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founded: 1998
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina News
Abandoning the idea of cohorts and the associated idea of a six-month residence period are the biggest changes Illumina Ventures is making to the program.
Illumina Hands Off Accelerator Program to Illumina Ventures
Illumina Ventures, an independent venture capital firm, will assume responsibility for the startup accelerator program and remake it as Illumina Ventures Labs.
Top Five Articles on GenomeWeb Last Week: Illumina's Future Direction; Biocartis Layoffs; More
Last week, GenomeWeb's readers were most interested in what the resignation of CEO Francis deSouza means for the future of Illumina and Grail.
Industry Groups Form European Coalition to Push for Better Comprehensive Genomic Profiling Access
A coalition of a trade group and drugmakers and diagnostics firms aims to share best practices and recommendations for better test reimbursement and uptake.
Illumina, AstraZeneca, Breast Cancer Canada Partner on Screening, Detection Grants
Breast Cancer Canada also announced the recipients of its annual Precision Oncology Research Grants, who received awards of either C$75,000 or C$50,000.